ITK Deficiency: How can EBV be Treated Before Lymphoma?
2015; Wiley; Volume: 62; Issue: 12 Linguagem: Inglês
10.1002/pbc.25648
ISSN1545-5017
AutoresFunda Çipe, Çiğdem Aydoğmuş, Nina K. Serwas, Deniz Tuğcu, Metin Demirkaya, Ferhan Akıcı Biçici, Arzu Babayiğit Hocaoğlu, Figen Doğu, Kaan Boztuğ,
Tópico(s)Tumors and Oncological Cases
ResumoPediatric Blood & CancerVolume 62, Issue 12 p. 2247-2248 Letter to the Editor ITK Deficiency: How can EBV be Treated Before Lymphoma? Funda Erol Cipe MD, Corresponding Author Funda Erol Cipe MD Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey Correspondence to: Funda Erol Cipe, Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey. E-mail: [email protected]Search for more papers by this authorCigdem Aydogmus MD, Cigdem Aydogmus MD Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorNina Kathrin Serwas, Nina Kathrin Serwas CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AustriaSearch for more papers by this authorDeniz Tuğcu MD, Deniz Tuğcu MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorMetin Demirkaya MD, Metin Demirkaya MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorFerhan Akıcı Biçici MD, Ferhan Akıcı Biçici MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorArzu Babayigit Hocaoglu, Arzu Babayigit Hocaoglu Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorFigen Doğu, Figen Doğu Department of Pediatric Allergy-Immunology, Ankara University School of Medicine, Ankara, TurkeySearch for more papers by this authorKaan Boztuğ, Kaan Boztuğ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, AustriaSearch for more papers by this author Funda Erol Cipe MD, Corresponding Author Funda Erol Cipe MD Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey Correspondence to: Funda Erol Cipe, Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, Turkey. E-mail: [email protected]Search for more papers by this authorCigdem Aydogmus MD, Cigdem Aydogmus MD Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorNina Kathrin Serwas, Nina Kathrin Serwas CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, AustriaSearch for more papers by this authorDeniz Tuğcu MD, Deniz Tuğcu MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorMetin Demirkaya MD, Metin Demirkaya MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorFerhan Akıcı Biçici MD, Ferhan Akıcı Biçici MD Department of Hematology-Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorArzu Babayigit Hocaoglu, Arzu Babayigit Hocaoglu Department of Pediatric Allergy-Immunology, Kanuni Sultan Suleyman Research and Training Hospital, Istanbul, TurkeySearch for more papers by this authorFigen Doğu, Figen Doğu Department of Pediatric Allergy-Immunology, Ankara University School of Medicine, Ankara, TurkeySearch for more papers by this authorKaan Boztuğ, Kaan Boztuğ CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, AustriaSearch for more papers by this author First published: 14 July 2015 https://doi.org/10.1002/pbc.25648Citations: 25 Conflict of interest: Nothing to declare. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1 Huck K, Feyen O, Niehues T, Rüschendorf F, Hübner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A. Females homozygous for an IL-2 inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 2009; 119: 1350– 1358. 2 Stepensky P, Weintraub M, Yanir A, Revel-Vilk S, Krux F, Huck K, Linka RM, Shaag A, Elpeleg O, Borkhardt A, Resnick IB. IL-2-inducible T-cell kinase deficiency: Clinical presentation and therapeutic approach. Haematologica 2011; 96: 472– 476. 3 Serwas NK, Cagdas D, Ban SA, Bienemann K, Salzer E, Tezcan I, Borkhardt A, Sanal O, Boztug K. Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T-cell lymphopenia. Blood 2014; 124: 655– 657. 4 Mansouri D, Mahdaviani SA, Khalilzadeh S, Mohajerani SA, Hasanzad M, Sadr S, Nadji SA, Karimi S, Droodinia A, Rezaei N, Linka RM, Bienemann K, Borkhardt A, Masjedi MR, Velayati AA. IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection. Int Arch Allergy Immunol 2012; 158: 418– 422. 5 Linka RM, Risse SL, Bienemann K, Werner M, Linka Y, Krux F, Synaeve C, Deenen R, Ginzel S, Dvorsky R, Gombert M, Halenius A, Hartig R, Helminen M, Fischer A, Stepensky P, Vettenranta K, Köhrer K, Ahmadian MR, Laws HJ, Fleckenstein B, Jumaa H, Latour S, Schraven B, Borkhardt A. Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases. Leukemia 2012; 26: 963– 971. 6 Ghosh S, Bienemann K, Boztug K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency—clinical and molecular aspects. J Clin Immunol 2014; 34: 892– 899. 7 Vezina HE, Balfour HH, Jr., Weller DR, Anderson BJ, Brundage RC. Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis. J Clin Pharmacol 2010; 50: 734– 742. 8 Pisapia R, Mariano A, Rianda A, Testa A, Oliva A, Vincenzi L. Severe EBV hepatitis treated with valganciclovir. Infection 2013; 41: 251– 254. 9 Shamriz O, Vilk SR, Wolf DG, Ta-Shma A, Averbuch D, Weintraub M, Stepensky P. Hematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders. Clin Immunol 2014; 151: 79– 83. Citing Literature Volume62, Issue12December 2015Pages 2247-2248 ReferencesRelatedInformation
Referência(s)